IGGA
HEPA

Iron Gate Global Advisors’s Hepion Pharmaceuticals HEPA Stock Holding History

Iron Gate Global Advisors’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13
Closed -$10.3K – 94
2023
Q1 		$10.3K Buy
+13
New +$9.6K ﹤0.01% 87

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Iron Gate Global Advisors's HEPA Position: Q2 2023 in Review

Iron Gate Global Advisors sold out of Hepion Pharmaceuticals (HEPA) in Q2 2023, closing a stake of 13 shares — an estimated $10.3K sold.

Iron Gate Global Advisors first reported a position in HEPA in Q1 2023 and held it in 1 quarter. The position peaked at $10.3K in Q1 2023. 16 funds tracked by Wall St. Rank hold HEPA as of Q2 2023.

  • Iron Gate Global Advisors reported no remaining Hepion Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Iron Gate Global Advisors sold 13 Hepion Pharmaceuticals shares in Q2 2023, an estimated $10.3K.
  • Iron Gate Global Advisors first reported a position in Hepion Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Iron Gate Global Advisors's Hepion Pharmaceuticals position peaked at $10.3K in Q1 2023.
  • 16 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2023.

Based on Iron Gate Global Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.